Researchers Describe Aggressive Breast Cancer Molecular Mechanism
|
By LabMedica International staff writers Posted on 11 Nov 2016 |

Image: The structural model of the SIRT2 protein (Photo courtesy of Wikimedia Commons).
Cancer researchers have found that SIRT2, a member of the sirtuin family of enzymes, stabilizes Slug, a transcription factor that promotes the development, growth, and spread of basal-like breast cancer.
Overabundance of Slug protein is common in human cancer and represents an important determinant underlying the aggressiveness of basal-like breast cancer (BLBC). Despite its importance, this transcription factor is rarely mutated in BLBC, and the mechanism of its deregulation in cancer remains unknown.
To better understand the link between Slug and BLBC, investigators at Tufts University School of Medicine (Boston, MA, USA) screened BLBC cultures for factors that would stabilize Slug activity.
They reported in the October 25, 2016, online edition of the journal Cell Reports that Slug underwent acetylation-dependent protein degradation and identified the deacetylase SIRT2 as a key mediator of this post-translational mechanism. SIRT2 inhibition rapidly destabilized Slug, whereas SIRT2 overexpression extended Slug stability. SIRT2 deacetylated Slug protein at lysine residue K116 to prevent Slug degradation.
SIRT2 was frequently amplified and highly expressed in BLBC. Genetic depletion and pharmacological inactivation of SIRT2 in BLBC cells reversed Slug stabilization, caused the loss of clinically relevant pathological features of BLBC, and inhibited tumor growth. Without SIRT2, tumor cells had a more than 60% reduction in invasive capacity compared to normal basal-like tumor cells. SIRT2-depleted cells also had significantly decreased capacity for growth and self-renewal. This diminished malignancy could be reversed by artificially introducing Slug protein back into cells.
"Breast cancer is not one disease, and of the several distinct subtypes, basal-like breast cancer represents the most aggressive form. By targeting a master transcription factor regulator in basal-like cells, we were able to reduce malignant behaviors," said senior author Dr. Charlotte Kuperwasser, professor of developmental, molecular, and chemical biology at Tufts University School of Medicine. "Our findings now provide a molecular rationale for new approaches to help improve the poor clinical outcomes currently associated with these cancers."
"Cancer cells find sophisticated ways to regulate essential proteins they need for their survival and growth. The transcriptional factor Slug is one such protein and is often tightly regulated in both normal and cancer cells. While we have found that SIRT2 plays an important role in prolonging Slug expression, it is too soon to know whether targeting SIRT2 will be sufficient to abolish Slug entirely in cancer cells and therefore lead to tumor regression," said Dr. Kuperwasser. "A significant amount of work remains to be done before we can verify if targeting SIRT2 can be an Achilles' heel for treating basal-like breast cancers."
Related Links:
Tufts University School of Medicine
Overabundance of Slug protein is common in human cancer and represents an important determinant underlying the aggressiveness of basal-like breast cancer (BLBC). Despite its importance, this transcription factor is rarely mutated in BLBC, and the mechanism of its deregulation in cancer remains unknown.
To better understand the link between Slug and BLBC, investigators at Tufts University School of Medicine (Boston, MA, USA) screened BLBC cultures for factors that would stabilize Slug activity.
They reported in the October 25, 2016, online edition of the journal Cell Reports that Slug underwent acetylation-dependent protein degradation and identified the deacetylase SIRT2 as a key mediator of this post-translational mechanism. SIRT2 inhibition rapidly destabilized Slug, whereas SIRT2 overexpression extended Slug stability. SIRT2 deacetylated Slug protein at lysine residue K116 to prevent Slug degradation.
SIRT2 was frequently amplified and highly expressed in BLBC. Genetic depletion and pharmacological inactivation of SIRT2 in BLBC cells reversed Slug stabilization, caused the loss of clinically relevant pathological features of BLBC, and inhibited tumor growth. Without SIRT2, tumor cells had a more than 60% reduction in invasive capacity compared to normal basal-like tumor cells. SIRT2-depleted cells also had significantly decreased capacity for growth and self-renewal. This diminished malignancy could be reversed by artificially introducing Slug protein back into cells.
"Breast cancer is not one disease, and of the several distinct subtypes, basal-like breast cancer represents the most aggressive form. By targeting a master transcription factor regulator in basal-like cells, we were able to reduce malignant behaviors," said senior author Dr. Charlotte Kuperwasser, professor of developmental, molecular, and chemical biology at Tufts University School of Medicine. "Our findings now provide a molecular rationale for new approaches to help improve the poor clinical outcomes currently associated with these cancers."
"Cancer cells find sophisticated ways to regulate essential proteins they need for their survival and growth. The transcriptional factor Slug is one such protein and is often tightly regulated in both normal and cancer cells. While we have found that SIRT2 plays an important role in prolonging Slug expression, it is too soon to know whether targeting SIRT2 will be sufficient to abolish Slug entirely in cancer cells and therefore lead to tumor regression," said Dr. Kuperwasser. "A significant amount of work remains to be done before we can verify if targeting SIRT2 can be an Achilles' heel for treating basal-like breast cancers."
Related Links:
Tufts University School of Medicine
Latest BioResearch News
- Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
- New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
- New Immune Target Could Support More Precise High Blood Pressure Treatment
- New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders
- Researchers Identify Shared Molecular Networks Behind Fatigue-Related Illnesses
- Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
- Whole-Blood Extracellular Vesicle Analysis Captures Molecular Signals Missed by Plasma Testing
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
- Computational Tool Identifies Central Asthma Genes for Target Discovery
- Molecular Pathway Reveals Driver of Triple-Negative Breast Cancer Spread
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
Channels
Clinical Chemistry
view channel
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more
Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more
Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read moreMolecular Diagnostics
view channel
Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination
Reliable confirmation of mpox can be difficult where multiple rash-causing illnesses co-circulate and laboratory capacity is limited. Although PCR is central to case detection, contamination during specimen... Read more
Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors
Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read moreBlood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery
Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more
Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer
Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read moreMicrobiology
view channel
Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more
Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
Lyme disease and other tick-borne illnesses cause overlapping symptoms, making them difficult to distinguish clinically. The Centers for Disease Control and Prevention estimates that more than 476,000... Read morePathology
view channel
Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more
Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read more
Machine Learning Cytology Tool Improves Cancer Cell Identification
Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more
Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read moreTechnology
view channel
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing
Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals
Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read moreSputum-Based Lung Cancer Test Technology Granted Hong Kong Patent
Asia accounts for nearly two-thirds of lung cancer cases worldwide, with an estimated 1.6 million new diagnoses across the region each year. Against this substantial disease burden, a newly granted patent... Read more







